Chemical modification of the multitarget neuroprotective compound fisetin.
暂无分享,去创建一个
[1] P. Maher,et al. Fisetin Lowers Methylglyoxal Dependent Protein Glycation and Limits the Complications of Diabetes , 2011, PloS one.
[2] Xin Wang,et al. Central nervous system agents for ischemic stroke: neuroprotection mechanisms. , 2011, Central nervous system agents in medicinal chemistry.
[3] P. Maher,et al. Control of redox state and redox signaling by neural antioxidant systems. , 2011, Antioxidants & redox signaling.
[4] D. Mozaffarian,et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.
[5] J. Purcell,et al. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. , 2011, Human molecular genetics.
[6] J. Kraus,et al. Neuroprotective Effects of N‐Alkyl‐1,2,4‐oxadiazolidine‐3,5‐diones and Their Corresponding Synthetic Intermediates N‐Alkylhydroxylamines and N‐1‐Alkyl‐3‐carbonyl‐1‐hydroxyureas against in vitro Cerebral Ischemia , 2010, ChemMedChem.
[7] P. Maher. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin , 2009, Genes & Nutrition.
[8] P. Maher,et al. Lactacidosis modulates glutathione metabolism and oxidative glutamate toxicity , 2009, Journal of neurochemistry.
[9] L. Su,et al. Sulfuric Acid Promoted Condensation Cyclization of 2‐(2‐(Trimethylsilyl)ethynyl)anilines with Arylaldehydes in Alcoholic Solvents: An Efficient One‐Pot Synthesis of 4‐Alkoxy‐2‐arylquinolines , 2009 .
[10] J. Kraus,et al. Potential neuroprotective drugs in cerebral ischemia: new saturated and polyunsaturated lipids coupled to hydrophilic moieties: synthesis and biological activity. , 2009, Journal of medicinal chemistry.
[11] L. Su,et al. Sulfuric acid promoted condensation cyclization of 2-(2-(trimethylsilyl) ethynyl)anilines with arylaldehydes in alcoholic solvents: an efficient one-pot synthesis of 4-alkoxy-2-arylquinolines , 2009 .
[12] Christian Gerloff,et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. , 2009, Stroke.
[13] S. Kuo,et al. Metabolism and pharmacokinetics of 3,3',4',7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. , 2009, Journal of agricultural and food chemistry.
[14] K. Suk,et al. Suppressive effects of flavonoid fisetin on lipopolysaccharide-induced microglial activation and neurotoxicity. , 2008, International immunopharmacology.
[15] Spencer J. Williams,et al. Understanding the cardioprotective effects of flavonols: discovery of relaxant flavonols without antioxidant activity. , 2008, Journal of medicinal chemistry.
[16] P. Maher,et al. A novel approach to screening for new neuroprotective compounds for the treatment of stroke , 2007, Brain Research.
[17] M. Pangalos,et al. Drug development for CNS disorders: strategies for balancing risk and reducing attrition , 2007, Nature Reviews Drug Discovery.
[18] E. Castellano,et al. Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. , 2007, Bioorganic & medicinal chemistry.
[19] S. Hitchcock,et al. Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.
[20] A. Shuaib,et al. Therapeutic strategies for the treatment of stroke. , 2006, Drug discovery today.
[21] P. Maher. A comparison of the neurotrophic activities of the flavonoid fisetin and some of its derivatives , 2006, Free radical research.
[22] H. Pajouhesh,et al. Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.
[23] P. Maher,et al. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal‐regulated kinase activation , 2004, Journal of neurochemistry.
[24] Han-Wei Chu,et al. Regioselective hydroxylation of 2-hydroxychalcones by dimethyldioxirane towards polymethoxylated flavonoids , 2004 .
[25] Yael Bromberg,et al. Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells , 2003, Neuroscience Letters.
[26] B. S. Winkler,et al. Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms. , 2003, Experimental eye research.
[27] P. Maher,et al. Oxytosis: A novel form of programmed cell death. , 2001, Current topics in medicinal chemistry.
[28] I. Gozes,et al. VIP-related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells , 2000, Journal of Molecular Neuroscience.
[29] C. Oliveira,et al. Distinct Glycolysis Inhibitors Determine Retinal Cell Sensitivity to Glutamate-Mediated Injury , 1999, Neurochemical Research.
[30] P. Lipton,et al. Ischemic cell death in brain neurons. , 1999, Physiological reviews.
[31] A. Reshef,et al. Activation and inhibition of protein kinase C protect rat neuronal cultures against ischemia-reperfusion insult , 1997, Neuroscience Letters.
[32] W. Mathews,et al. The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion. , 1996, The Journal of pharmacology and experimental therapeutics.
[33] H. Ueda,et al. 3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors. , 1993, Journal of medicinal chemistry.
[34] P. Reiner,et al. A pharmacological model of ischemia in the hippocampal slice , 1990, Neuroscience Letters.
[35] W. Schaffner,et al. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.
[36] H. Kourai,et al. Syntheses of 5,6,7- and 5,7,8-trioxygenated 3',4'-dihydroxyflavones having alkoxy groups and their inhibitory activities against arachidonate 5-lipoxygenase. , 1986, Journal of medicinal chemistry.
[37] P. Andrews,et al. A common structural model for central nervous system drugs and their receptors. , 1986, Journal of medicinal chemistry.